Background: Some patients present clinical features of both asthma and chronic obstructive pulmonary disease (COPD), which has led to the recent proposal of asthma-COPD overlap (ACO) as a diagnosis. Fractional exhaled nitric oxide (FeNO) is a candidate biomarker to diagnose ACO. We assessed the effect of an add-on treatment with budesonide/formoterol (BUD/FM) combination in patients with ACO, which was diagnosed by FeNO. Methods: This was a prospective, single-arm, open-label, before and after comparison study. Subjects included 83 patients with COPD who attended outpatient clinics for routine checkups at Shizuoka General Hospital between June and November 2016. All patients fulfilled the GOLD definition of COPD and were receiving long-acting muscarinic antagonist (LAMA) or LAMA/long-acting β 2 agonist (LABA) combinations. After an 8-week run-in period, BUD/FM was added to the patients with FeNO levels of ≥35 ppb, defined as having ACO. For patients receiving LAMA/LABA, BUD/FM was added after the discontinuation of LABA. The modified British Medical Research Council (mMRC) score, COPD assessment test (CAT) score, spirometric indices, forced oscillation parameters, and FeNO were assessed before and after 8 weeks of BUD/ FM add-on treatment. Results: Twenty-four patients (28.9%) had FeNO levels ≥ 35 ppb, and
Introduction
Since some patients present clinical features of both asthma and chronic obstructive pulmonary disease (COPD), the asthma-COPD overlap (ACO) has recently been proposed as a diagnosis [1] . Clinically, it can be challenging to distinguish asthma from COPD, especially in smokers and older adults. ACO is heterogeneous and includes different phenotypes: COPD with eosinophilic airway inflammation is one such phenotype, accounting for 10% -40% of patients with COPD [2] [3] [4] .
Several reports have suggested that high sputum and blood eosinophil counts in patients with COPD are associated with specific clinical phenotypes defined by 1) more frequent exacerbations and 2) better response to inhaled corticosteroids (ICS) for exacerbation prevention [5] [6] [7] [8] [9] . In addition, ICS therapy may reduce the rate of decline of forced expiratory volume in 1 second (FEV1) in patients with high blood eosinophil counts [10] . Eosinophilic airway inflammation can be noninvasively measured through the airway using induced sputum analysis and fractional exhaled nitric oxide (FeNO) [11] . However, induced sputum is less repeatable and reliable than FeNO due to the complexities of sputum collection. The blood eosinophil count acts as an indirect biomarker of eosinophilic airway inflammation. Regarding treatment, there is no evidencebased consensus on ACO treatment since patients with COPD, complicated with asthmatic components, have been excluded from large-scale clinical trials.
Based on the evidence of benefit of ICS/long-acting β 2 -agonist (LABA) combination in asthma, we hypothesized that ICS/LABA can also be utilized for managing the eosinophilic COPD phenotype of ACO. In the present study, we assessed the effects of add-on treatment with a budesonide/formoterol (BUD/FM) combination in patients with COPD with high FeNO levels who were receiving a long-acting muscarinic antagonist (LAMA) or LAMA/LABA.
Methods

Subjects
Outpatients with COPD at Shizuoka General Hospital, seen between June and November 2016 were enrolled in this study. All patients fulfilled the definition of GOLD, and the COPD grading was based on the GOLD classification [12] . The 
Study Design
This is a prospective, single-arm, open-label, before-and-after comparison study ( Figure 1 
Assessment of Symptoms
The modified Medical Research Council (mMRC) score was used to evaluate dyspnea in daily living, grading from 0 (only get breathless with strenuous exercise) to 4 (too breathless to leave the house or breathless when dressing) [13] .
The COPD assessment test (CAT) (Japanese version, supplied by GlaxoS-mithKline, Japan) consists of eight items (cough, phlegm, chest tightness, breathlessness going up hills/stairs, activity limitations at home, confidence leaving home, sleep, and energy) that assess and quantify the symptoms and the impact of COPD [14] . Each item is scored from 0 to 5, giving a total score range from 0 to 40, corresponding to the best and worst health statuses, respectively.
FeNO
FeNO was measured using an online method at a flow of 50 mL/s using an NO [15] . A FeNO of 35 ppb was selected as a cutoff point for high
FeNO based on a previous study [16] .
Forced Oscillation Technique (FOT) and Spirometry
Measurement of FOT and spirometry were performed in that order to avoid any influence of forced breathing. Broadband frequency FOT was performed using the MostGraph-01 (Chest M.I. Co. Ltd., Tokyo, Japan) in accordance with standard recommendations [17] . We used Rrs at 5 and 20 Hz (R5 and R20, respectively) and the difference between R5 and R20 (R5 -R20) as an indicator of the frequency dependence of Rrs. We also used Xrs at 5 Hz ( 
Study Outcomes
The primary outcome was the change in FEV1 between weeks 0 and 8. Secondary outcomes included changes in mMRC and CAT scores, forced vital capacity, forced oscillation parameters, and FeNO levels.
Long-Term Follow-Up
From 8 weeks until 12 months after the initiation of add-on treatment, patients attended outpatient clinics for routine checkups and the medication regimens were maintained as long as possible. Occurrences of exacerbation or pneumonia were assessed using medical records after 12 months.
Statistical Analyses
The quantitative data were summarized as means with standard deviations and were compared using t-tests. The 
Results
The study flow and the clinical characteristics of the subjects at baseline are shown in Figure 2 and Next, we stratified the patients into two groups based on a minimal clinically important improvement of two or more points on their CAT scores. Table 3 shows the characteristics of groups with and without improvement. The group with improved CAT scores had higher CAT scores at baseline than those without improvement. There were no differences noted in blood eosinophil counts, FeNO levels, IgE, or lung function. The ROC analysis for predicting CAT score improvement revealed an AUC of 0.836 for baseline CAT with the best cutoff value of 10 points at baseline (Figure 4 ).
During long-term follow-up, until 12 months after initiation of add-on treatment, one of the 14 patients developed pneumonia but none experienced exacerbations. Three patients quit BUD/FM during the follow-up period.
Discussion
We prospectively assessed the effects of an add-on treatment with BUD/FM in patients with an eosinophilic COPD phenotype of ACO. The results revealed that the CAT scores, including total, cough, phlegm, and chest tightness showed significant improvement, and 10 out of 17 patients (58.8%) showed ≥ 2 points improvement, a minimal clinically important difference. The ROC analysis for predicting CAT score improvement revealed the best cutoff value of 10 points at baseline.
Recent evidence pertaining to type 2 inflammation indicates that FeNO is primarily driven by IL-13 and IL-4 and its levels often correlate with eosinophilic airway inflammation driven by IL-5 [21] . We detected IL-13-or IL-4-related eosinophilic airway inflammation using FeNO measurements in patients with COPD. We selected 35 ppb as a cutoff point for high and low FeNO levels in accordance with s previously reported research on severe asthma [16] . Based on these criteria, we diagnosed 24 out of 83 patients with COPD (28.9%) as having ACO. Researchers in a previous report investigated the prevalence rate of ACO in 331 patients with COPD and identified 54 patients (16.3%) by using 35 ppb as the cutoff point [22] . A possible explanation for the difference may be that 40% of the patients were receiving ICS or oral corticosteroids in the previous study.
In this study, we compared patients with high FeNO and those with low FeNO and found that the former had higher blood eosinophil counts than the latter.
However, the correlation between FeNO and blood eosinophil counts was modest, which suggests that the patients with high FeNO in this study could not be selected based on blood eosinophil counts. Neither could the patients with high There was no significant change in FEV1 after 8 weeks of add-on treatment,
whereas the CAT scores significantly improved, including total, cough, phlegm, and chest tightness. Importantly, 10 patients (58.8%) reached a minimal clinically important difference. BUD/FM was added on to LAMA alone or after Open Journal of Respiratory Diseases withdrawal of LABA without a washout period. It seems that there was no room for improvement of spirometric indices after initiation of the add-on treatment.
In contrast, CAT score improvement is explained by the necessity of not only LABA but also ICS. Together with the improvement in FeNO, ICS was necessary for the patients with high FeNO to improve in this study. Previous research reported the usefulness of BUD/FM in the management of COPD [23] [24] . However, patients with ACO were historically excluded from such studies. Currently, there is no consensus on ACO treatment [25] . Whether ICS/LABA, ICS/LAMA, or triple therapy is beneficial for patients with ACO requires further research.
Conclusion
In conclusion, add-on treatment with BUD/FM improves symptoms in patients with ACO, as determined by high FeNO levels.
